Published in Oncol Rep on May 01, 2007
Synthesis and biological evaluation of [(18)F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter. Eur J Nucl Med Mol Imaging (2010) 1.71
Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med (2008) 1.63
Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging (2007) 1.23
64Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Mol Imaging Biol (2009) 1.10
A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression. J Nucl Med (2009) 1.09
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. Cancer Res (2009) 1.08
Applications of 211At and 223Ra in targeted alpha-particle radiotherapy. Curr Radiopharm (2011) 1.04
Astatine Radiopharmaceuticals: Prospects and Problems. Curr Radiopharm (2008) 0.89
Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting. Bioconjug Chem (2011) 0.88
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opin Biol Ther (2016) 0.85
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer. Expert Opin Drug Deliv (2014) 0.85
Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res (2006) 2.46
Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med (2010) 1.75
Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood (2002) 1.67
Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res (2007) 1.67
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood (2009) 1.66
Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int (2005) 1.58
Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res (2007) 1.40
First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med (2014) 1.31
Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel (2007) 1.30
Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging (2009) 1.30
EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol (2007) 1.28
Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem (2010) 1.27
Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med (2003) 1.26
Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med (2012) 1.24
On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med (2009) 1.23
Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood (2002) 1.23
(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem (2007) 1.22
Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol (2008) 1.19
Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med (2005) 1.16
In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules. Bioconjug Chem (2007) 1.13
In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. Nucl Med Biol (2010) 1.12
Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination. Bioconjug Chem (2007) 1.10
211AtCl@US-tube nanocapsules: a new concept in radiotherapeutic-agent design. Small (2007) 1.09
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. Cancer Res (2009) 1.08
Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging (2008) 1.06
Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjug Chem (2005) 1.06
Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study. Transplantation (2004) 1.06
Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging (2006) 1.06
Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl Med Biol (2007) 1.06
Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden. J Neurooncol (2003) 1.05
Radiohalogens for imaging and therapy. Chem Soc Rev (2004) 1.04
In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm (2005) 1.03
A streptavidin-biotin binding system that minimizes blocking by endogenous biotin. Bioconjug Chem (2002) 1.03
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. Blood (2007) 1.03
Design of an optimized scaffold for affibody molecules. J Mol Biol (2010) 1.02
Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging (2006) 1.02
99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging (2007) 1.02
Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug Chem (2007) 1.01
Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med (2013) 1.01
Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med (2010) 1.00
Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. Blood (2009) 0.99
Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol (2003) 0.99
Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. Bioconjug Chem (2002) 0.99
Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med (2006) 0.99
Quantitative imaging and correction for cascade gamma radiation of 76Br with 2D and 3D PET. Phys Med Biol (2002) 0.98
Engineering of affibody molecules for therapy and diagnostics. Methods Mol Biol (2012) 0.98
Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood (2003) 0.98
Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res (2013) 0.98
Pretargeted radioimmunotherapy for B-cell lymphomas. Clin Cancer Res (2007) 0.97
Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. J Nucl Med (2011) 0.96
Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med (2009) 0.96
Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. Cancer Res (2007) 0.96
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas. Blood (2007) 0.96
Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med (2013) 0.95
Elimination of stabilised hyaluronan from the knee joint in healthy men. Clin Pharmacokinet (2002) 0.95
Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma. Theranostics (2012) 0.94
Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One (2013) 0.94
Update: affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm (2007) 0.93
Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule. Biotechnol Appl Biochem (2009) 0.92
Exploring (57)Co as a new isotope for brachytherapy applications. Med Phys (2012) 0.91
Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds. Bioconjug Chem (2004) 0.91
Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol (2010) 0.91
Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. Eur J Nucl Med Mol Imaging (2011) 0.90
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood (2011) 0.89
Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. J Nucl Med (2011) 0.89
Biotin reagents in antibody pretargeting. 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl- and nido-carboranyl-biotin derivatives. Bioconjug Chem (2004) 0.89
Minor changes in effective half-life during fractionated 177Lu-octreotate therapy. Acta Oncol (2011) 0.88
Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med (2007) 0.88
Reagents for astatination of biomolecules. 3. Comparison of closo-decaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211. Bioconjug Chem (2009) 0.87
Differences in radiosensitivity between three HER2 overexpressing cell lines. Eur J Nucl Med Mol Imaging (2008) 0.87
Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF. Tumour Biol (2010) 0.87
Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules. Bioconjug Chem (2008) 0.87
[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res (2007) 0.87
Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. Drug Discov Today (2012) 0.86
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants. Bioconjug Chem (2010) 0.86
HER-2--a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol (2002) 0.86
Pilot study of a (213)bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation. Transplantation (2010) 0.85
Synthesis, radioiodination, and biodistribution of some nido- and closo-monocarbon carborane derivatives. Nucl Med Biol (2004) 0.85
HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules. J Med Chem (2013) 0.85
Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects. Int J Oncol (2010) 0.85
Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus. Tumour Biol (2012) 0.85
Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA. Bioconjug Chem (2013) 0.84
Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. Eur J Nucl Med Mol Imaging (2009) 0.84
Biological response to radiation therapy. Acta Oncol (2003) 0.84